You are here

Two New Drugs for Underdiagnosed Disease of the Heart

First Medicines for Adults With Wild-type or Hereditary ATTR-CM

The FDA has approved tafamidis meglumine and tafamidis (Vyndaquel® and VyndamaxTM, Pfizer Inc.) for the treatment of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. Both drugs are oral formulations of the first-in-class transthyretin stabilizer tafamidis.

The rare and life-threatening ATTR-CM is characterized by the buildup of abnormal deposits of amyloid protein in the heart, causing restrictive cardiomyopathy and progressive heart failure.

The approval was based on data from the pivotal phase 3 Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT), the first global, double-blind, randomized, placebo-controlled clinical study to investigate a pharmacological therapy for ATTR-CM treatment.

In the trial, tafamidis meglumine significantly reduced all-cause mortality and frequency of cardiovascular-related hospitalizations compared with placebo, over 30 months. Tafamidis meglumine also showed significant improvement compared with placebo in patients’ functional capacity and health status at six months and continuing through 30 months.

Previously, the sole treatment options were symptom management and, rarely, heart (or heart and liver) transplant. Approximately 100,000 people in the U.S are thought to have ATTR-CM, but only one to two percent of them have been diagnosed. Following diagnosis, the median life expectancy in patients with ATTR-CM is approximately two to 3.5 years.

Source: Pfizer Inc, May 6, 2019

Recent Headlines

First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status